Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 13, 2022

Efficacy of Abemaciclib Plus Fulvestrant in PIK3CA- or ESR1-Mutant Advanced Breast Cancer

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Clinical Significance of PIK3CA and ESR1 Mutations in circulating tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib Plus Fulvestrant
Clin. Cancer Res 2022 Feb 04;[EPub Ahead of Print], SM Tolaney, M Toi, P Neven, J Sohn, EM Grischke, A Llombart-Cussac, H Soliman, H Wang, S Wijayawardana, VM Jansen, LM Litchfield, GW Sledge

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading